Can Aceminib cure chronic myelogenous leukemia? Analysis of efficacy and limitations

Asciminib as a newBCR-ABL1 tyrosine kinase inhibitor (TKI) has received widespread attention for its application in the treatment of chronic myelogenous leukemia (CML). It not only effectively targets patients who are resistant to traditional TKIs (such as imatinib), but also has a unique mechanism of action that can target the specific domain-SH2 domain in the BCR-ABL1 fusion gene, thereby inhibiting the growth and spread of leukemia cells.

Aximini has performed extremely well in clinical trials. According to clinical data, aceminib is effective in controlling the condition of most CML patients, especially those who are resistant to traditional treatments. For example, in some pivotal clinical trials, aceminib demonstrated stronger anti-leukemia effects than other traditional TKIs and was well tolerated.

However, although aceminib has significant efficacy, it does not cureCML. Like other TKIs, Aceminib works more by inhibiting the growth of cancer cells, delaying the progression of the disease and maintaining long-term remission. In the early stages of treatment, Aceminib can effectively control the condition of CML and significantly reduce the number of leukemia cells, but it does not completely eliminate cancer cells. Therefore, although aceminib can help patients enter long-term remission, it has not yet been proven to have the ability to cure chronic myelogenous leukemia.

In addition, the use of acemini still faces some limitations. First, the effects of drugs vary among individuals, and resistance may develop, especially with long-term use. Some patients may develop resistance to aximinib after a period of treatment, thus affecting the efficacy of the drug. Secondly, aximini also has certain side effects, such as fatigue, headache, gastrointestinal discomfort, etc. Although most of the adverse reactions are relatively mild, they still need to be closely monitored during the treatment process.

Reference materials:https://www.novartis.com/our-products/pipeline/asciminib